These results are consistent with the findings of Ito and colleagues, in which up‐regulated TRIM32 was related to an increased risk of recurrence and an undesirable prognosis in patients with GC.21 Furthermore, a series of in vitro and in vivo experiments here revealed that a knockdown of TRIM32 suppresses cell proliferation, migration, invasion and tumour growth, whereas overexpression of TRIM32 yields the opposite results. This evidence concerns the gene TRIM32 and gastric cancer.